title: Vasopressors for hypotensive shock.
abstract: BACKGROUND
  Initial goal-directed resuscitation for hypotensive shock usually includes administration of intravenous fluids, followed by initiation of vasopressors. Despite obvious immediate effects of vasopressors on haemodynamics, their effect on patient-relevant outcomes remains controversial. This review was published originally in 2004 and was updated in 2011 and again in 2016.
  
  
  OBJECTIVE
  Our objective was to compare the effect of one vasopressor regimen (vasopressor alone, or in combination) versus another vasopressor regimen on mortality in critically ill participants with shock. We further aimed to investigate effects on other patient-relevant outcomes and to assess the influence of bias on the robustness of our effect estimates.
  
  
  METHODS
  We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015 Issue 6), MEDLINE, EMBASE, PASCAL BioMed, CINAHL, BIOSIS and PsycINFO (from inception to June 2015). We performed the original search in November 2003. We also asked experts in the field and searched meta-registries to identify ongoing trials.
  
  
  METHODS
  Randomized controlled trials (RCTs) comparing various vasopressor regimens for hypotensive shock.
  
  
  METHODS
  Two review authors abstracted data independently. They discussed disagreements between them and resolved differences by consulting with a third review author. We used a random-effects model to combine quantitative data.
  
  
  RESULTS
  We identified 28 RCTs (3497 participants) with 1773 mortality outcomes. Six different vasopressors, given alone or in combination, were studied in 12 different comparisons.All 28 studies reported mortality outcomes; 12 studies reported length of stay. Investigators reported other morbidity outcomes in a variable and heterogeneous way. No data were available on quality of life nor on anxiety and depression outcomes. We classified 11 studies as having low risk of bias for the primary outcome of mortality; only four studies fulfilled all trial quality criteria.In summary, researchers reported no differences in total mortality in any comparisons of different vasopressors or combinations in any of the pre-defined analyses (evidence quality ranging from high to very low). More arrhythmias were observed in participants treated with dopamine than in those treated with norepinephrine (high-quality evidence). These findings were consistent among the few large studies and among studies with different levels of within-study bias risk.
  
  
  CONCLUSIONS
  We found no evidence of substantial differences in total mortality between several vasopressors. Dopamine increases the risk of arrhythmia compared with norepinephrine and might increase mortality. Otherwise, evidence of any other differences between any of the six vasopressors examined is insufficient. We identified low risk of bias and high-quality evidence for the comparison of norepinephrine versus dopamine and moderate to very low-quality evidence for all other comparisons, mainly because single comparisons occasionally were based on only a few participants. Increasing evidence indicates that the treatment goals most often employed are of limited clinical value. Our findings suggest that major changes in clinical practice are not needed, but that selection of vasopressors could be better individualised and could be based on clinical variables reflecting hypoperfusion.
authors.affiliation: Department of Cardiology, Universitätsklinikum Sankt Pölten, Sankt Pölten, Austria.
authors.forename: Gunnar
authors.initials: G
authors.lastname: Gamper
authors.forename: Christof
authors.initials: C
authors.lastname: Havel
authors.forename: Jasmin
authors.initials: J
authors.lastname: Arrich
authors.forename: Heidrun
authors.initials: H
authors.lastname: Losert
authors.forename: Nathan Leon
authors.initials: NL
authors.lastname: Pace
authors.forename: Marcus
authors.initials: M
authors.lastname: Müllner
authors.forename: Harald
authors.initials: H
authors.lastname: Herkner
mesh_terms: D004359:Drug Therapy, Combination; D006801:Humans; D007022:Hypotension / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D012769:Shock / Q000188:drug therapy* / Q000401:mortality; D012772:Shock, Septic / Q000188:drug therapy / Q000401:mortality; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014662:Vasoconstrictor Agents